New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:41 EDTZGNXZogenix reports positive results from Relday Phase 1 clinical trial
Zogenix announced positive single-dose pharmacokinetic, or PK, results from the Phase 1 clinical trial of Relday, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia. Adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products. Based on the favorable safety and PK profile demonstrated with the 25 mg and 50 mg once-monthly doses tested in the Phase 1 trial, Zogenix has extended the current study to include a 100 mg dose of the same formulation. The addition of this dose arm to the study will enable evaluation of dose proportionality across the full dose range that would be anticipated to be used in clinical practice. Positive results from this study extension would better position Zogenix to begin a multi-dose clinical trial, which would provide the required steady-state PK and safety data prior to initiating Phase 3 development studies. Zogenix expects to complete the extension of the Phase 1 clinical trial during Q2.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:21 EDTZGNXZogenix 4.75M share Secondary priced at $18.00
The deal size was increased to 4.75M shares from 3.8M shares. Leerink and Stifel acted as joint book running managers for the offering.
July 28, 2015
19:10 EDTZGNXOn The Fly: After Hours Movers
Subscribe for More Information
16:40 EDTZGNXZogenix files to sell 3.8M shares of common stock
Subscribe for More Information
July 23, 2015
17:15 EDTZGNXIntegrated Core Strategies reports 5.6% passive stake in Zogenix

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use